Cryoport Navigates Q2 with Equity Shifts and Diversified Investments

TL;DR

**Cryoport's Q2 shows steady financial management and equity growth, making it a stable, albeit not explosive, play in life sciences logistics.**

AI Summary

Cryoport, Inc. (CYRX) filed its 10-Q for the quarter ended June 30, 2025, showing a continued focus on its life sciences logistics. While specific revenue and net income figures are not provided in the given excerpt, the filing indicates changes in equity components. Common stock increased from 2024-12-31 to 2025-06-30, and additional paid-in capital also saw an increase over the same period. Retained earnings and accumulated other comprehensive income balances are reported at various quarter-ends, suggesting ongoing operational activities. The company's investment portfolio includes U.S. Treasury Securities, Mutual Funds, and Corporate Debt Securities as of June 30, 2025, and December 31, 2024, indicating a diversified approach to managing its cash reserves. The filing also notes subsequent events occurring between July 1, 2025, and July 31, 2025, which could impact future financial performance. The company maintains its focus within the pharmaceutical preparations industry.

Why It Matters

This 10-Q provides a snapshot of Cryoport's financial health and strategic positioning in the critical life sciences logistics sector. Investors should note the shifts in equity, particularly common stock and additional paid-in capital, which can signal capital raises or employee stock activity. The diversified investment portfolio suggests prudent cash management, potentially offering stability in a volatile market. For employees, continued operational activity and financial stability imply job security and growth opportunities. In a competitive landscape with players like World Courier and Marken, Cryoport's ability to manage its capital and investments is crucial for maintaining its market share and funding future innovations in cold chain logistics.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing indicates stable financial management through diversified investments in U.S. Treasury Securities, Mutual Funds, and Corporate Debt Securities, specific revenue and net income figures are absent from the provided data. This lack of core performance metrics prevents a full assessment of operational profitability and potential losses, which could indicate underlying business risks not immediately apparent.

Analyst Insight

Investors should look for Cryoport's full financial statements to assess revenue growth and net income, as these are critical for understanding operational performance. Consider the implications of subsequent events noted between July 1, 2025, and July 31, 2025, as these could materially impact future quarters.

Key Numbers

• 2025-06-30 — End of reporting period (The quarter for which the 10-Q was filed.)
• 2025-08-12 — Filing date (Date the 10-Q was officially filed with the SEC.)
• 0001124524 — Central Index Key (CIK) (Unique identifier for Cryoport, Inc. with the SEC.)
• 104 — Public Document Count (Number of documents included in the filing.)

Key Players & Entities

• Cryoport, Inc. (company) — filer of the 10-Q
• CYRX (company) — ticker symbol for Cryoport, Inc.
• U.S. Treasury Securities (dollar_amount) — investment held by Cryoport
• Mutual Funds (dollar_amount) — investment held by Cryoport
• Corporate Debt Securities (dollar_amount) — investment held by Cryoport
• World Courier (company) — competitor in life sciences logistics
• Marken (company) — competitor in life sciences logistics

FAQ

Industry Context

Cryoport, Inc. operates within the pharmaceutical preparations industry, a sector characterized by high growth potential driven by advancements in biotechnology, cell and gene therapies, and the increasing demand for specialized logistics solutions. The competitive landscape includes other logistics providers and internal capabilities of pharmaceutical companies. Key industry trends involve the need for temperature-controlled supply chains, regulatory compliance, and efficient global distribution networks for sensitive biological materials.

Regulatory Implications

As a company involved in the life sciences supply chain, Cryoport is subject to stringent regulations concerning the handling, storage, and transportation of biological materials. Compliance with Good Distribution Practices (GDP) and other international standards is critical. Any failure to adhere to these regulations could result in significant penalties, reputational damage, and disruption to client operations.

What Investors Should Do

1. Monitor subsequent events disclosed in the 10-Q.
2. Analyze changes in equity components.
3. Review the composition and performance of the investment portfolio.

Key Dates

• 2025-06-30: End of reporting period for the 10-Q filing. — Marks the end of the fiscal quarter for which financial statements are presented.
• 2025-08-12: 10-Q filing date. — Indicates the official submission date of the quarterly report to the SEC.
• 2025-07-01: Start of subsequent events period. — The period following the balance sheet date during which significant events are disclosed.
• 2025-07-31: End of subsequent events period. — The period following the balance sheet date during which significant events are disclosed.

Glossary

us-gaap:CommonStockMember

Represents the shares of common stock issued by the company. (Changes in this account reflect equity transactions related to common stock, such as issuances or repurchases.)

us-gaap:AdditionalPaidInCapitalMember

The amount received from the issuance of stock in excess of its par or stated value. (An increase here typically signifies the company has issued new shares, potentially for capital raising or stock-based compensation.)

us-gaap:RetainedEarningsMember

The cumulative net income of the company that has not been distributed to shareholders as dividends. (Reflects the company's historical profitability and its policy on dividend distribution.)

us-gaap:AccumulatedOtherComprehensiveIncomeMember

A component of equity representing unrealized gains and losses on certain investments and foreign currency translations. (Provides insight into the impact of non-operating items on the company's overall equity.)

us-gaap:USTreasurySecuritiesMember

Debt securities issued by the U.S. Department of the Treasury. (Indicates a portion of the company's cash reserves is invested in low-risk government debt.)

us-gaap:MutualFundMember

An investment vehicle that pools money from many investors to invest in securities like stocks, bonds, and money market instruments. (Shows diversification of the company's investment portfolio beyond direct debt holdings.)

us-gaap:CorporateDebtSecuritiesMember

Debt instruments issued by corporations. (Represents investments in debt issued by other companies, carrying a different risk profile than government securities.)

us-gaap:SubsequentEventMember

Events that occur after the balance sheet date but before the financial statements are issued. (These events can have a material impact on the company's financial position and are disclosed to provide a more complete picture to investors.)

Year-Over-Year Comparison

While specific comparative figures for revenue and net income are not detailed in this excerpt, the 10-Q indicates changes in equity components such as common stock and additional paid-in capital between the periods ending December 31, 2024, and June 30, 2025. The presence of retained earnings and accumulated other comprehensive income balances at various quarter-ends suggests ongoing operational activities and potential shifts in profitability and equity valuation compared to prior periods.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value CYRX The Nasdaq Stock Mar

Filing Documents

• cyrx-20250630x10q.htm (10-Q) — 3276KB
• cyrx-20250630xex31d1.htm (EX-31.1) — 14KB
• cyrx-20250630xex31d2.htm (EX-31.2) — 13KB
• cyrx-20250630xex32d1.htm (EX-32.1) — 17KB
• cyrx-20250630x10q004.jpg (GRAPHIC) — 8KB
• 0001558370-25-011127.txt ( ) — 14979KB
• cyrx-20250630.xsd (EX-101.SCH) — 77KB
• cyrx-20250630_cal.xml (EX-101.CAL) — 107KB
• cyrx-20250630_def.xml (EX-101.DEF) — 376KB
• cyrx-20250630_lab.xml (EX-101.LAB) — 706KB
• cyrx-20250630_pre.xml (EX-101.PRE) — 576KB
• cyrx-20250630x10q_htm.xml (XML) — 3449KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

ITEM 1. Financial Statements Condensed Consolidated Balance Sheets at June 30, 2025 (Unaudited) and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 6 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 40

Controls and Procedures

ITEM 4. Controls and Procedures 40

OTHER INFORMATION

PART II. OTHER INFORMATION 41

Legal Proceedings

ITEM 1. Legal Proceedings 41

Risk Factors

ITEM 1A. Risk Factors 41

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 41

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities 41

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures 41

Other Information

ITEM 5. Other Information 41

Exhibits

ITEM 6. Exhibits 43

SIGNATURES

SIGNATURES 44 Table of Contents Cryoport, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share data) June 30, December 31, 2025 2024 (unaudited) ASSETS Current Assets: Cash and cash equivalents $ 243,416 $ 34,137 Short-term investments 182,559 216,460 Accounts receivable, net 33,409 25,304 Inventories 23,035 21,476 Prepaid expenses and other current assets 7,071 7,944 Current assets held for sale — 36,251 Total current assets 489,490 341,572 Property and equipment, net 81,565 80,013 Operating lease right-of-use assets 38,206 39,920 Intangible assets, net 143,590 147,927 Goodwill 18,713 20,569 Deposits 2,096 1,951 Deferred tax assets 267 842 Long-term assets held for sale — 70,699 Total assets $ 773,927 $ 703,493 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable and other accrued expenses $ 14,756 $ 15,895 Accrued compensation and related expenses 9,400 11,209 Deferred revenue 1,677 1,061 Current portion of operating lease liabilities 3,889 3,399 Current portion of finance lease liabilities 427 315 Current portion of convertible senior notes, net of discount of $ 0.1 million — 14,298 Current portion of notes payable — 143 Current portion of contingent consideration — 2,808 Current liabilities held for sale — 15,435 Total current liabilities 30,149 64,563 Convertible senior notes, net of current portion and discount of $ 1.7 million and $ 2.3 million, respectively 184,504 183,919 Notes payable, net of current portion 1,328 1,114 Operating lease liabilities, net of current portion 37,441 38,551 Finance lease liabilities, net of current portion 934 800 Deferred tax liabilities 985 804 Other long-term liabilities 2,567 296 Contingent consideration, net of current portion 628 3,751 Long-term liabilities held for sale — 7,797

View Full Filing

View this 10-Q filing on SEC EDGAR